These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12903649)

  • 21. Emerging strategies and agents to lower cardiovascular risk by increasing high density lipoprotein cholesterol levels.
    Greenfeder S
    Curr Med Chem; 2009; 16(2):144-56. PubMed ID: 19149567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Illuminating HDL--is it still a viable therapeutic target?
    Rader DJ
    N Engl J Med; 2007 Nov; 357(21):2180-3. PubMed ID: 17984168
    [No Abstract]   [Full Text] [Related]  

  • 23. Functional assessment of HDL: Moving beyond static measures for risk assessment.
    Rosenson RS
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):71-5. PubMed ID: 20094763
    [No Abstract]   [Full Text] [Related]  

  • 24. Fibrates, dyslipoproteinaemia and cardiovascular disease.
    Watts GF; Dimmitt SB
    Curr Opin Lipidol; 1999 Dec; 10(6):561-74. PubMed ID: 10680050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The failure of torcetrapib: was it the molecule or the mechanism?
    Tall AR; Yvan-Charvet L; Wang N
    Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):257-60. PubMed ID: 17229967
    [No Abstract]   [Full Text] [Related]  

  • 26. Novel therapies focused on the high-density lipoprotein particle.
    van Capelleveen JC; Brewer HB; Kastelein JJ; Hovingh GK
    Circ Res; 2014 Jan; 114(1):193-204. PubMed ID: 24385512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
    Neeli H; Rader DJ
    Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increasing HDL Cholesterol Levels.
    Brewer HB
    N Engl J Med; 2004 Apr; 350(15):1491-4. PubMed ID: 15071124
    [No Abstract]   [Full Text] [Related]  

  • 29. High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench.
    Levy Y
    Cardiovasc Res; 2008 Mar; 77(4):614-5. PubMed ID: 18187459
    [No Abstract]   [Full Text] [Related]  

  • 30. High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm.
    Tuteja S; Rader DJ
    Clin Pharmacol Ther; 2014 Jul; 96(1):48-56. PubMed ID: 24713591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implications of torcetrapib failure for the future of HDL therapy: is HDL-cholesterol the right target?
    von Eckardstein A
    Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):345-58. PubMed ID: 20222814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Research digest: next-generation lipoprotein therapeutics.
    Berberich AJ; Hegele RA
    Lancet Diabetes Endocrinol; 2020 Mar; 8(3):190. PubMed ID: 32085826
    [No Abstract]   [Full Text] [Related]  

  • 33. Hyperlipidaemia and cardiovascular disease: low HDL-cholesterol as a therapeutic target in statin-treated patients: a role for nicotinic acid (niacin)?
    Choudhury RP
    Curr Opin Lipidol; 2010 Apr; 21(2):161-2. PubMed ID: 20616630
    [No Abstract]   [Full Text] [Related]  

  • 34. Therapies to increase high-density lipoprotein cholesterol and their effect on cardiovascular outcomes and regression of atherosclerosis.
    Venkatesh PK; Caskey D; Reddy PC
    Am J Med Sci; 2008 Jul; 336(1):64-8. PubMed ID: 18626239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cholesteryl ester transfer protein inhibition: effect on reverse cholesterol transport?
    Rensen PC; Havekes LM
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):681-4. PubMed ID: 16556861
    [No Abstract]   [Full Text] [Related]  

  • 36. Non-adherence to lipid-lowering therapies: a need for more studies to evaluate reasons for medication non-adherence.
    Wong MC; Wang HH; Liu KS
    Int J Clin Pract; 2011 Dec; 65(12):1321-2. PubMed ID: 22093540
    [No Abstract]   [Full Text] [Related]  

  • 37. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target.
    Bhatt A; Rohatgi A
    Curr Atheroscler Rep; 2016 Jan; 18(1):2. PubMed ID: 26710794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus.
    Shimabukuro M; Higa M; Tanaka H; Shimabukuro T; Yamakawa K; Masuzaki H
    Diabet Med; 2011 Jul; 28(7):856-64. PubMed ID: 21244474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-density lipoprotein cholesterol as a therapeutic target to reduce cardiovascular events.
    Fonarow GC; Watson KE
    Am Heart J; 2004 Jun; 147(6):939-41. PubMed ID: 15199335
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.